DOCSLIB.ORG

13974/02 JV/Dp 1 DG H II COUNCIL of the EUROPEAN UNION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
13974/02 JV/Dp 1 DG H II COUNCIL of the EUROPEAN UNION COUNCIL OF Brussels, 8 November 2002 THE EUROPEAN UNION 13974/02 CORDROGUE 94 NOTE from : EMCDDA and EUROPOL to : Council Secretariat Subject : Joint information from EMCDDA and Europol to the Horizontal Working Party on Drugs of the Council of the European Union in the framework of the Joint Action on new synthetic drugs 13974/02 JV/dp 1 DG H II EN Draft joint information from EMCDDA and EUROPOL to the Horizontal Working Party on Drugs of the Council of the European Union in the framework of the Joint Action on new synthetic drugs. 1. Since the adoption of the Joint Action in June 1997 and the setting-up of the Early-warning System, a certain number of synthetic substances have been detected and monitored. 2. Depending on different variables such as the gravity of the consequences (deaths), the nature of evidences (overdoses), the frequency of findings (not anecdotic), the scope of the presence in the market (notifications and seizures), the EMCDDA and EUROPOL: a) have produced joint reports for some of these substances, when the initial estimation of risks required it; b) have continued to collect information for the others, with less evident risks, in order to complete the picture with the new findings. 3. On the basis of the EMCDDA-EUROPOL joint reports, the EMCDDA’s extended Scientific Committee has been requested to carry out the risk assessment of these substances. Thus, risk- assessment reports have been produced for the substances MBDB, 4-MTA, GHB, ketamine, PMMA. 4. Following the risk-assessment exercises, and according to the procedures, decisions were taken to put under control some of these substances (4-MTA, PMMA) and to continue to monitor the others (MBDB, GHB, ketamine) for which no sufficient evidence was available to put these under control. 5. In the meantime, EMCDDA and EUROPOL have obtained more information on a series of substances with different levels of evidence and danger. This is the case for the substances 2C-T-2, 2C-T-7, 2C-I, TMA-2, BZP, TFMPP, PMEA, DOC, 5-MeO-DMT, 5-MeO-DIPT, DXM, DPT, A-MT, ALEPH-7. 13974/02 JV/dp 2 DG H II EN 6. This report aims to present the current state of knowledge of the last mentioned substances according to the same methodology of the EMCDDA/EUROPOL joint reports. A fiche by substance is annexed. 7. The Horizontal Working Party on Drugs is kindly requested to take note of this information and to give instructions about the substances for which a risk assessment is considered to be necessary and the substances for which the monitoring should continue. 13974/02 JV/dp 3 DG H II EN ANNEX FACT SHEET 2C-I 1. Chemical and physical description 2C-I 2C-B Chemical name: 2,5-dimethoxy-4-iodo-phenethylamine (2C-I) Synonyms: 4-Iodo-2,5-dimethoxy-Phenethylamine or: (2,5-dimethoxy-4-iodophenyl)-2-aminoethane; or: 4-Iod-2,5-dimethoxyphenethylazan (Germany) Chemical formula : Anal. (C10H15ClINO2) C,H,N Pharmaceutical form: pill/tablet format; or in powder form. ROUTES OF ADMINISTRATION:. ORALLY Common dose range: 10-20 mg Duration 6-10h Street name: “2C-I” ; “i” (“i” logo) 2. Effects: 2C-I seems to have been ‘frequently’compared to the controlled drug 2C-B (UN Schedule II) for their analogous chemical structures and subjective effects. With regard to the latter, the entactogen (producing empathy) and energetic properties of both drugs are described by Shulgin as quite similar. Hallucinogenic properties are apparently comparable in low doses, but much weaker in 2C-I than in 2C-B in high doses. 2C- I is generally taken orally and used in the same ways or to enhance the effects of ‘ecstasy’. The typical dose needed is 20mg, so it is therefore stronger than MDMA (typically 190mg). Apparently, it affects users in a similar way to MDMA except that it is a bit more introspective, like strong cannabis and has stimulatory effects. 3. Health risks: The delayed onset of action (90 minutes) of 2C-I could potentially lead users to take too much of the drug if they become impatient (by topping up before the effects hit) and provoke adverse effects. Reported fatalities: None in the EU 13974/02 JV/dp 4 DG H II EN 4. Legal status: 2C-I is a ring-substituted phenethylamine which is currently not listed under any of the Schedules of the 1971 UN Convention on Psychotropic Substances. EU: 2C-I was put under permanent control in Germany on 19 June 2001. The substance was already under control on a temporary basis in 1999. The arguments for placing these kinds of drugs under permanent control can be found in the legal text (‘Fünfzehnte Betäubungsmittelrechts-Änderungsverordnung-15. BtMÄndV’, 19 June 2001), i.e.: (i) substances being used as ‘ecstasy drugs’; and (ii) produced by illegal labs modifying the chemical structure of illegal drugs in order to achieve that these will not fall under the law (‘designer drugs’). In the UK, 2C-I comes within the definition of a controlled substance by virtue of a generic description as set out in paragraph (i)(c) of the Misuse of Drugs Act 1977 (Controlled Drug) Declaration Order 1987. Denmark has controlled 2C-I since May 2002 (’Bekendtgørelse nr. 305 af 16. maj 2002 om ændring af bekendtgørelse om euforiserende stoffer’). US: non-controlled Reports to EMCDDA (A= Reporting Form; B= other) DENMARK (A): notification on 14 May 2002 of one seizure in May 2002 of one white pill 120 mg 2C-I with the “i” logo and of 2 ml in liquid form. UK (B): one case in a seizure in 1999. SWEDEN (B) : one seizure in 1999. 13974/02 JV/dp 5 DG H II EN FACT SHEET 2C-T-2 1. Chemical and physical description 2C-T-2 2C-T-7 Chemical name : 4-ethylthio-2,5-dimethoxyphenethylamine (2C-T-2) Synonyms: 4-Ethylsulfanyl-2,5-dimethoxyphenethylazan (Germany) 2C-T-2, as 2C-T-7, is a carbon phenethylamine homologue of previously made three carbon amphetamine, having the alpha-methyl group removed. Molecular formula : C12-H19-N-O2-S Pharmaceutical form: mostly in tablet; or in powder form (hydrochloride salt). Marquis test: orange-red (“fresh salmon”) ROUTES OF ADMINISTRATION:. ORALLY OR INTRANASALLY Street name: 2C-T-2 2. Effects Very similar to 2C-T-7. The effects of 2C-T-2 seems to share some general similarities with mescaline or 2C-B : powerful visual effects, mood lifting, sense of well being, increased appreciation of music, etc. “There is a considerable parallel between 2C-T-2 and 2C-T-7. (...) With 2C-T-2, there is more of a tendency to have physical disturbances such as nausea and diarrhea. And the experience is distinctly shorter” (A. Shulgin). Moreover, “Individual sensitivities seem to vary greatly with 2C-T-7, in sharp contrast to 2C-T-2” (source: synthesis of user reports, Murple/Erowid, Feb. 2001) Dose range: 10 - 35 mg (average = 20 orally ; 13 intranasally) Duration : 6 - 8 h 3. Health risks: As for the other 24 drugs of the 2C-T family, 2C-T-2's clinical safety profile is not well known nor researched. The most severe side-effects (source: user reports) are : nausea, vomiting, delirium, dissociation, loss of memory, panic attacks and a strong depression of CNS which could provoke convulsions, suffocation or lead to physical injury. Combination of 2C-T-2 with MDMA increases health risks. Similarly to 2C-T-7, sniffing the drug in powder form increases secondary effects and the risks of severe (even lethal) overdoses. 2C-T-2 and MAOIs (commonly found in a number of anti-depressants) are a potentially dangerous combination (risk of serotonergic syndrome). Reported fatalities: None in the EU. 13974/02 JV/dp 6 DG H II EN 4. Legal status: EU: - Germany: placed under Schedule I on Oct 7, 1998. (listed as 4-Ethylsulfanyl-2,5-dimethoxyphenethylazan); - Sweden: placed under “emergency scheduling” on April 1, 1999; - Netherlands: classified as an unregistered pharmaceutical as of April 12, 1999. Unlicensed manufacture, sale, import, trade and possession of this substance can be prosecuted. US: non-controlled drug. Reports to EMCDDA: (A= Reporting Form; B= Other ) FRANCE (A): notified on 23/09/2002: one tablet, collected by SINTES in August 2002 (white, no logo, sold as “mescaline”). GERMANY (A): notified in March 1998: several seizures reported by BKA in February 1998 of a total of 20 tablets (170 mg) with “X” logo. SWEDEN: (A): notified on 15/01/1999: one seizure on 10/07/98: 0,07g powder. SWEDEN (B): six seizures in 1998, three seizures in 1999, two in 2000, one in 2001. DENMARK: (B) one seizure of 2000 tablets on 26/01/2001. NETHERLANDS (B): 1998 (DIMS Report) SPAIN (B) : 1998 13974/02 JV/dp 7 DG H II EN FACT SHEET 2C-T-7 1. Chemical and physical description 2C-T-7 2C-T-2 Chemical name : 2,5-dimethoxy-4-(n)-propylthiophenethylamine (synonym: “PT-DM-PEA”) Chemical formula : C13-H21-N-O2-S Identification: NMR results are available on the erowid website. 2C-T-7, a potent psychedelic phenethylamine which was first synthesized by Alexander Shulgin in the eighties, is a sulphur analogue of the UN controlled drug 2C-B (4-bromo-2,5-dimethoxyphenethylamine - Schedule II). Pharmaceutical form: in powder form (hydrochloride salt), in capsule or in pill format. 2C-T-7 reacts to Marquis reagent assay with a salmon orange colour. ROUTES OF ADMINISTRATION: INTRANASALLY (“SNIFFED”) OR ORALLY (MOST COMMON ROUTE). DOSE RANGE : 5-50 MG ORALLY (2,5-35 MG INTRANASALLY) Street name: T-7, Beautiful, Lucky 7, 7-up, 7th Heaven, Tweety-Bird Mescaline, Tripstasy (US), Red Raspberry (Canada), Blue Mystic (brand name in the Netherlands – “Ying-Yang” logo).
Load more

Recommended publications
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
    [Show full text]
  • Download Full Article As
    Article Alkaloids Detection in Commonly Found Medicinal Plants with Marquis Reagent Daniel Alejandro Ocampo-Bustos1 and María Elena Cano-Ruiz1 1 Tecnológico de Monterrey High School, Cuernavaca, Mexico. SUMMARY identity of social groups. Many of the medicinal plants have Alkaloids are a class of nitrogenous organic their healing properties known by empirical use through time, compounds of plant origin that may have important but these medicinal plants may contain active ingredients physiological actions on humans. They include many with tested pharmacological properties. One possibility is that drugs and poisons, but some alkaloids in low doses some of the active ingredients in medicinal plants belong to the have health benefits as well. Traditional medicinal group of alkaloids, which can be determined by a colorimetric plants may contain alkaloids as active ingredients, chemical reaction with the Marquis reagent. The reagent is but this is not well-understood. The Marquis reagent dripped onto the substance being tested, and if an alkaloid exists as a simple qualitative colorimetric method is present, a color change appears (5). The Marquis reagent to determine the presence of alkaloids in medicinal is traditionally composed of a mixture of formaldehyde and plants. The Marquis reagent test was assayed in concentrated sulfuric acid. medicinal plants by first optimizing the formulation Originally, the Marquis reagent was used for testing of the reagent using poppy seeds and lavender as many different alkaloids, and the results from those studies the positive and negative controls. Then using the were the base for developing the color scales that are optimized formulation of Marquis reagent in the extracts of 11 medicinal plants with known claims of used as a reference to determine the specific alkaloid health benefits.
    [Show full text]
  • Acquired Synaesthesia Following 2C-B Use
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Greenwich Academic Literature Archive Acquired synaesthesia following 2C-B use • Authors • Authors and affiliations • Steliana Yanakieva (Department of Psychology, Goldsmiths, University of London) • David P. Luke (Department of Psychology, Social Work and Counselling, University of Greenwich) • Ashok Jansari (Department of Psychology, Goldsmiths, University of London) • Devin B. Terhune (Department of Psychology, Goldsmiths, University of London) Letter to Editor This study was previously presented at Bridging senses: New developments in synesthesia (Royal Society, London, UK, 22–23 October 2018). Psychedelic drugs reliably trigger experiences that closely resemble synaesthesia (Luke and Terhune 2013), a condition in which inducer stimuli will reliably and automatically elicit atypical concurrent experiences (Ward 2013). These transient episodes are considered controversial because they do not meet behavioural diagnostic criteria for developmental synaesthesia (Terhune et al. 2016). However, if these behavioural markers are attributable to the consolidation of synaesthetic associations over time (Terhune et al. 2016), they should be observed in cases of acquired synaesthesia. Here we report a case of drug-induced acquired synaesthesia (LW) that meets standard diagnostic criteria for developmental synaesthesia. LW is a 29-year-old male who reports continuously experiencing multiple forms of synaesthesia for over 7 years since ingesting approximately 70–150 mg of 2,5-dimethoxy-4- bromophenethylamine (2C-B) (Papaseit et al. 2018), which greatly exceeds the normal dosage (12–24 mg) (Shulgin and Shulgin 1990) (see Supplementary Materials). LW was contrasted against 10 non-synaesthete healthy controls, all of whom provided informed written consent.
    [Show full text]
  • Drugs Policy in the New Programme for Government
    Issue 37 Spring 2011 drugnetIRELAND Newsletter of the Alcohol and Drug Research Unit Drugs policy in the new Hearing the voices of service users programme for government As this newsletter goes to press, the government See pages 5–7. has not announced its intentions with regard to the future location of the Offi ce of the Minister for Drugs and its functions. However, the new programme for government, Government for National Recovery 2011–2016,1 contains a To have Drugnet Ireland number of actions related to drugs policy. This delivered to your desktop, article attempts to identify the implications of sign up on the NDC website these actions should they be implemented. Actions related to crime and justice www.drugsandalcohol.ie We will introduce roadside drug testing programmes to combat the problem of driving under the infl uence of drugs. The development of reliable roadside testing procedure has been a challenging issue for many > From research to policy: countries. At present the Garda Síochána, the Department of Transport and the Medical Bureau of Road Safety are collaborating in the development of a scheme to introduce US-style roadside tests the Sax Institute seminar on suspected drug drivers to accompany roadside alcohol tests. > HSE plan for drug- We will ensure that violent offenders and other serious offenders serve appropriate prison sentences while related services in 2011 at the same time switching away from prison sentences and towards less costly non-custodial options for non-violent and less serious offenders. > Update on drug-related The fi rst Bill introduced by the new Minister for Justice and Law Reform is the Criminal Justice deaths and deaths (Community Service) (Amendment) (No.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • Misuse of Drugs Regulations 2017 2 [173]
    STATUTORY INSTRUMENTS. S.I. No. 173 of 2017 ———————— MISUSE OF DRUGS REGULATIONS 2017 2 [173] S.I. No. 173 of 2017 MISUSE OF DRUGS REGULATIONS 2017 ARRANGEMENT OF REGULATIONS PART 1 Preliminary and General 1. Citation and commencement. 2. Interpretation. PART 2 Issuing of Prescriptions by Registered Nurses and Registered Midwives 3. Provisions applicable to practitioners who are registered nurses or regis- tered midwives. 4. Person may refuse to supply drug if reasonable cause to believe conditions referred to in regulation 3 have not been satisfied. PART 3 Production, Supply, Importation and Exportation of Controlled Drugs 5. General prohibition. 6. Licences. 7. Administration. 8. Exemption for practitioners, pharmacists, etc. 9. Supply. PART 4 Possession of Controlled Drugs 10. General exemptions. 11. Exemption to possess butan-1,4-diol or dihydrofuran-2(3H)-one. 12. Exemption for midwives in respect of pentazocine and pethidine. 13. General authorities. PART 5 Documentation and Record-Keeping 14. Documents to be obtained by a supplier. [173] 3 15. Form of prescriptions. 16. Supply on prescription. 17. Marking of containers. 18. Documents required for export of controlled drugs. 19. Keeping of registers for drugs in Schedules 1 and 2. 20. Record-keeping in particular cases for drugs in Schedule 2. 21. Keeping of records for drugs in Schedules 3 and 4. 22. Preservation of registers, etc. 23. Preservation of records for drugs in Schedules 3, Part 1 of Schedule 4, and Schedule 5. 24. Furnishing of information with respect to controlled drugs. PART 6 Miscellaneous 25. Destruction of certain drugs. 26. Disposal of certain drugs on cessation of business.
    [Show full text]
  • Drugs and Medical Devices Group
    The Deputy Administrator of the Drug Enforcement Administration (DEA) issued a notice of intent temporarily placing the substance 2,5-dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7), including its optical isomers, salts, and salts of isomers into Schedule I of the Federal Controlled Substances Act (CSA). 2C-T-7 is structurally related to the Schedule I substance 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and it has those structural features of phenethylamines which are necessary for stimulant and/or hallucinogenic activity. There is no approved therapeutic use of 2C-T-7 in the United States, and the safety of this substance has never been demonstrated. This action was based on the following: (1) 2,5-dimethoxy-4-(n)-propylthiophenethylamine is structurally and pharmacologically related to other Schedule I hallucinogens; (2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has no accepted therapeutic use in the United States and is not safe for use under medical supervision; and, (3) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has a high potential for abuse, similar to other Schedule I phenethylamines. Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Chapter 481, Health and Safety Code, at least thirty-one days have expired since notice of the above referenced action was published in the Federal Register, and in my capacity as Commissioner of the Texas Department of Health, I do hereby order that the substance 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers be added to Schedule I of the Texas Controlled Substances Act.
    [Show full text]
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Piperazine (Street Names: “TFMPP” Or “Molly”. Often Found in Combination with BZP: “A2”, “Legal E” Or “Legal X”)
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 1-[3-(Trifluoro-methyl)-phenyl]piperazine (Street Names: “TFMPP” or “Molly”. Often found in combination with BZP: “A2”, “Legal E” or “Legal X”) October 2019 Introduction: Illicit Uses: 1-[3-(Trifluoro-methyl)-phenyl]piperazine (TFMPP) is TFMPP is being promoted as a legal alternative to an industrial chemical. It is often abused in combination MDMA at raves (all-night dance parties) as TFMPP or with benzylpiperazine (BZP), a schedule I controlled “Molly” and is often sold in combination with BZP as substance. The Drug Enforcement Administration (DEA) “ecstasy”, or “A2", “legal E” or “legal X” in order to enhance temporarily controlled TFMPP in 2002 as a schedule I its spectrum of effects. TFMPP may be abused alone for hallucinogen under the Controlled Substances Act (CSA) its hallucinogenic effects. TFMPP is generally administered because of its abuse potential and lack of accepted orally as either powder, tablets or capsules. Other routes medical use or safety. However, based on the scientific of administration include smoking and snorting. and medical evaluation conducted by the Food and Drug Administration (FDA) and the National Institute on Drug User Population: Abuse (NIDA), the Department of Health and Human Youth and young adults are the main abusers of Services (DHHS) did not recommend control of TFMPP. TFMPP. Accordingly, TFMPP was no longer controlled under the CSA after March 18, 2004. Recently, there has been an Illicit Distribution: escalation in the abuse of TFMPP in the United States as The National Forensic Laboratory Information System evidenced by the increasing encounters of this substance (NFLIS) is a DEA database that collects scientifically by law enforcement officials in various states and the verified data on drug items and cases submitted to and District of Columbia.
    [Show full text]
  • Gc/Ms Assays for Abused Drugs in Body Fluids
    GC/MS ASSAYS FOR ABUSED DRUGS IN BODY FLUIDS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alchol, Drug Abuse, and Mental Health Administration GC/MS Assays for Abused Drugs in Body Fluids Rodger L. Foltz, Ph.D. Center for Human Toxicology University of Utah Salt Lake City, Utah 64112 Allison F. Fentiman, Jr., Ph.D. Ruth B. Foltz Battelle Columbus Laboratories Columbus, Ohio 43201 NIDA Research Monograph 32 August 1980 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the- art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alchol and Drug Abuse Research Center Harvard Medical School Mclean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C.
    [Show full text]